Navigation Links
Colonoscopy used to identify and remove flat colon lesions
Date:3/6/2008

OAK BROOK, Ill. March 6, 2008 A study released this week from researchers at the Veterans Affairs Palo Alto Healthcare System in California shows that non-polypoid colorectal neoplasms or flat colon lesions, are more common in Americans than previously thought and may have a greater association with cancer compared to polypoid neoplasms or the more commonly diagnosed colorectal polyp. The study appears in the March 5 issue of the Journal of the American Medical Association. Researchers identified these flat lesions through colonoscopy.

This study is very significant, as these flat lesions are more difficult to detect than the typical polyp during colorectal cancer screening, said Grace H. Elta, MD, FASGE, president of the American Society for Gastrointestinal Endoscopy (ASGE). Researchers identified these lesions in their study through colonoscopy, which has the ability to detect lesions of all sizes and is the only procedure that allows for the removal of lesions and polyps. Studies have shown that other imaging methods are ineffective at identifying even small polyps and miss flat lesions entirely. This study highlights the importance of quality colonoscopy screening. ASGE, as the standard-setting society for endoscopy, has issued quality indicators for colorectal cancer screening that define measures for improving quality in colonoscopy.

Flat lesions are challenging to detect because subtle findings through examination can be difficult to distinguish from the normal mucosa. As compared with the surrounding normal mucosa, the flat lesions appear to be slightly elevated, completely flat or slightly depressed.

The study examined data from a group of 1,819 patients, almost all men with an average age of 64, from July 2003 to June 2004 undergoing elective colonoscopy to estimate the prevalence of non-polypoid colorectal neoplasms (NP-CRNs), or flat lesions, and to characterize their association with colorectal cancer. Patients were divided into three groups; screening, surveillance and a group of patients with symptoms for colorectal cancer. Flat lesions were found in 170 people, approximately 10 percent. The surveillance group had the highest incidence with more than 15 percent who had flat lesions. Approximately six percent of the screening and symptoms groups had flat lesions. Researchers found that the flat growths were five times more likely to be cancerous than polyps.

Experts in gastrointestinal endoscopy will need to be more vigilant than ever in encouraging their patients to take their bowel prep as directed before the colonoscopy. Proper bowel prep is important so that the physician can clearly see the colon. This study also highlights the importance of not withdrawing too soon during the procedure, allowing the physician enough time to thoroughly examine the colon. According to ASGE quality indicators, withdrawal time should be six minutes or more. ASGE will continue to provide training and education to physicians to ensure that patients are receiving the highest quality of care possible, said Elta.


'/>"/>

Contact: Anne Brownsey
abrownsey@asge.org
630-570-5635
American Society for Gastrointestinal Endoscopy
Source:Eurekalert

Related medicine news :

1. Capsule endoscopy diagnoses more Crohns disease recurrence after surgery than colonoscopy
2. Virtual colonoscopy -- a new technology for colorectal cancer screening?
3. Colonoscopy Remains the Most Effective Screening Option for Colon Cancer
4. Virtual Colonoscopy an Effective Option: Study
5. Experts Offer Answers on Colonoscopy Options
6. First colonoscopy with removal of polyps linked to reduction in colon cancer death
7. Initial Colonoscopy Key to Cancer Detection
8. Minority patients prefer optical colonoscopy for colorectal cancer screening
9. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
10. Colonoscopy fears overcome when patients support patients
11. Colonoscopy Coaches Play Lifesaving Role
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... ... 2016 , ... The Florida Hospital Tampa Wound Healing Institute ... (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute as ... facilities have earned this distinction. This is the second time the Florida Hospital ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician ... of Drug and Alcohol Programs Gary Tennis ... insomnia medications, known as benzodiazepines, developed with the ... "Benzodiazepines are medications that are frequently prescribed for ... they are used with opioid pain medications, benzodiazepines ...
(Date:12/8/2016)... 2016  A new study by a pair of ... opioid therapy to treat chronic pain is not only ... harmful consequences, including death. Palliative care physicians ... Mehta , M.D., authored the study which provides a ... The study was published in the December 2016 edition ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, LLC ... obtained proof-of-mechanism for neflamapimod (previously code named VX-745), ... 2a clinical trials that demonstrated significant Alzheimer,s disease ... (12-week treatment) and Study 303 (6-week treatment) are ... in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: